A multiple ascending dosing study of PC-mAb in healthy volunteers.

Trial Profile

A multiple ascending dosing study of PC-mAb in healthy volunteers.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs PC mAb (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Coronary artery restenosis
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Aug 2017 New trial record
    • 30 Jan 2016 According to an Athera Biotechnologies media release, dosing has been initiated in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top